Literature DB >> 15043804

Restless Legs Syndrome.

Suzanne Lesage1, Christopher J. Earley.   

Abstract

In the past 10 years, restless legs syndrome (RLS) has gained recognition as a common sleep disorder. There are several therapeutic options in treating patients with RLS. RLS causes significant sleep disturbance and negatively impacts on patient quality of life. Pharmacologic treatment can result in improved sleep and quality of life issues. RLS patients should be evaluated for iron deficiency anemia; iron replacement in deficient patients may lead to a resolution of symptoms or may reduce the severity of their symptoms. For patients with daily symptoms, the initial therapy is dopamine agonists. Low doses given in the evening or 2 hours before bed provide adequate relief of symptoms for many RLS patients. Augmentation can be seen with all dopamine agents, but is most prevalent with levodopa. Levodopa therapy is best used for milder intermittent symptoms or in aggravating situations, such as long car rides. Opiates and antiepileptics remain a beneficial therapy for RLS and are useful in patients who experience pain as part of their RLS. Newer anticonvulsants may provide additional treatment options, but they have yet to undergo clinical trials. Intravenous iron also may provide relief of RLS symptoms; however, dosing and safety issues have not been fully evaluated in a RLS population.

Entities:  

Year:  2004        PMID: 15043804     DOI: 10.1007/s11940-004-0013-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  44 in total

Review 1.  Clinical practice. Restless legs syndrome.

Authors:  Christopher J Earley
Journal:  N Engl J Med       Date:  2003-05-22       Impact factor: 91.245

2.  Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron.

Authors:  K A Lee; M E Zaffke; K Baratte-Beebe
Journal:  J Womens Health Gend Based Med       Date:  2001-05

3.  Associations between symptoms of inattention, hyperactivity, restless legs, and periodic leg movements.

Authors:  Ronald D Chervin; Kristen Hedger Archbold; James E Dillon; Kenneth J Pituch; Parviz Panahi; Ronald E Dahl; Christian Guilleminault
Journal:  Sleep       Date:  2002-03-15       Impact factor: 5.849

4.  Epidemiology of restless legs symptoms in adults.

Authors:  B Phillips; T Young; L Finn; K Asher; W A Hening; C Purvis
Journal:  Arch Intern Med       Date:  2000-07-24

5.  Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.

Authors:  D Garcia-Borreguero; O Larrosa; Y de la Llave; K Verger; X Masramon; G Hernandez
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

6.  Restless legs syndrome in end-stage renal disease.

Authors:  J W Winkelman; G M Chertow; J M Lazarus
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

7.  Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.

Authors:  Svenja Happe; Cornelia Sauter; Gerhard Klösch; Bernd Saletu; Josef Zeitlhofer
Journal:  Neuropsychobiology       Date:  2003       Impact factor: 2.328

8.  Treatment of the restless legs syndrome with carbamazepine: a double blind study.

Authors:  W Telstad; O Sørensen; S Larsen; P E Lillevold; P Stensrud; R Nyberg-Hansen
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-11

9.  Iron and the restless legs syndrome.

Authors:  E R Sun; C A Chen; G Ho; C J Earley; R P Allen
Journal:  Sleep       Date:  1998-06-15       Impact factor: 5.849

10.  Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up.

Authors:  C von Scheele; V Kempi
Journal:  Arch Neurol       Date:  1990-11
View more
  1 in total

1.  Alterations in pain responses in treated and untreated patients with restless legs syndrome: associations with sleep disruption.

Authors:  Robert R Edwards; Phillip J Quartana; Richard P Allen; Seth Greenbaum; Christopher J Earley; Michael T Smith
Journal:  Sleep Med       Date:  2011-05-12       Impact factor: 3.492

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.